VSTMVerastem, Inc.

Nasdaq verastem.com


$ 2.42 $ -0.10 (-3.97 %)    

Tuesday, 20-Aug-2024 11:44:25 EDT
QQQ $ 479.72 $ -1.58 (-0.33 %)
DIA $ 408.04 $ -0.85 (-0.21 %)
SPY $ 558.03 $ -1.13 (-0.2 %)
TLT $ 98.54 $ 0.24 (0.24 %)
GLD $ 231.94 $ -1.78 (-0.76 %)
$ 2.49
$ 2.52
$ 2.41 x 200
$ 2.42 x 200
$ 2.40 - $ 2.52
$ 2.10 - $ 14.22
438,457
na
100.21M
$ 1.23
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 08-08-2024 06-30-2024 10-Q
2 05-09-2024 03-31-2024 10-Q
3 03-14-2024 12-31-2023 10-K
4 11-08-2023 09-30-2023 10-Q
5 08-08-2023 06-30-2023 10-Q
6 05-09-2023 03-31-2023 10-Q
7 03-14-2023 12-31-2022 10-K
8 11-03-2022 09-30-2022 10-Q
9 08-08-2022 06-30-2022 10-Q
10 05-09-2022 03-31-2022 10-Q
11 03-28-2022 12-31-2021 10-K
12 11-04-2021 09-30-2021 10-Q
13 08-02-2021 06-30-2021 10-Q
14 05-11-2021 03-31-2021 10-Q
15 03-18-2021 12-31-2020 10-K
16 11-09-2020 09-30-2020 10-Q
17 08-10-2020 06-30-2020 10-Q
18 05-07-2020 03-31-2020 10-Q
19 03-11-2020 12-31-2019 10-K
20 10-30-2019 09-30-2019 10-Q
21 08-01-2019 06-30-2019 10-Q
22 05-09-2019 03-31-2019 10-Q
23 03-12-2019 12-31-2018 10-K
24 11-07-2018 09-30-2018 10-Q
25 08-08-2018 06-30-2018 10-Q
26 05-03-2018 03-31-2018 10-Q
27 03-13-2018 12-31-2017 10-K
28 11-07-2017 09-30-2017 10-Q
29 08-08-2017 06-30-2017 10-Q
30 05-10-2017 03-31-2017 10-Q
31 03-23-2017 12-31-2016 10-K
32 11-07-2016 09-30-2016 10-Q
33 08-08-2016 06-30-2016 10-Q
34 05-09-2016 03-31-2016 10-Q
35 03-03-2016 12-31-2015 10-K
36 11-09-2015 09-30-2015 10-Q
37 08-10-2015 06-30-2015 10-Q
38 05-11-2015 03-31-2015 10-Q
39 03-10-2015 12-31-2014 10-K
40 10-30-2014 09-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 truist-securities-maintains-buy-on-verastem-lowers-price-target-to-15

Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from ...

 hc-wainwright--co-maintains-buy-on-verastem-lowers-price-target-to-7

HC Wainwright & Co. analyst Sean Lee maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $17.5 ...

 rbc-capital-maintains-outperform-on-verastem-lowers-price-target-to-13

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $16 to...

 verastem-q2-adj-061-beats-095-estimate-sales-1000k-miss-5000k-estimate

Verastem (NASDAQ:VSTM) reported quarterly losses of $(0.61) per share which beat the analyst consensus estimate of $(0.95) by 3...

 verastem-oncology-receives-fda-orphan-drug-designation-for-avutometinib-and-defactinib-for-the-treatment-of-pancreatic-cancer-expects-to-report-updated-data-from-the-ongoing-ramp-205-trial-in-first-line-metastatic-pancreatic-cancer-in-q1-2025

Expect to report updated data from the ongoing RAMP 205 trial in first-line metastatic pancreatic cancer in Q1 2025Verastem Onc...

 reported-earlier-verastem-oncology-prices-55m-public-offering-of-13333334-common-stock-warrants-and-pre-funded-warrants

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, to...

 verastem-oncology-announces-proposed-public-offering-of-common-stock-warrants-and-pre-funded-warrants-no-size-or-amount-disclosed

Verastem Oncology, (NASDAQ:VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, to...

 verastem-oncology-reveals-first-patient-dosed-with-gfh375vs-7375-a-kras-g12d-onoff-inhibitor-in-a-phase-12-trial-in-china-as-part-of-collaboration-with-genfleet-therapeutics

Verastem Oncology, a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced t...

 truist-securities-maintains-buy-on-verastem-lowers-price-target-to-18

Truist Securities analyst Srikripa Devarakonda maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from ...

 reported-wednesday-chinas-nmpa-approves-genfleet-and-verastem-oncologys-gfh375-for-kras-g12d-phase-iii-trials

 GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, a...

 alliance-global-partners-maintains-buy-on-verastem-lowers-price-target-to-20

Alliance Global Partners analyst Jeff Grampp maintains Verastem (NASDAQ:VSTM) with a Buy and lowers the price target from $3...

 rbc-capital-maintains-outperform-on-verastem-lowers-price-target-to-16

RBC Capital analyst Gregory Renza maintains Verastem (NASDAQ:VSTM) with a Outperform and lowers the price target from $32 to...

 hc-wainwright--co-reiterates-buy-on-verastem-maintains-175-price-target

HC Wainwright & Co. analyst Sean Lee reiterates Verastem (NASDAQ:VSTM) with a Buy and maintains $17.5 price target.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION